Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: An equivalence study

Nuclear Medicine Communications

Volumn 21, Issue 11, 2000, Pages 1071-1078

  Kok, S W ^a   Smit, J W ^a   De Craen, A J M ^a   Goslings, B M ^a   Van ECK Smit, B L F ^a   Romijn, J A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; GOITER; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MALE; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; RADIATION DOSE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GOITER; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; ORGAN SIZE; RADIOTHERAPY DOSAGE; RECURRENCE; TREATMENT OUTCOME;

EID: 0034331770     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200011000-00014     Document Type: Review

References (42)

1. Tunbridge WMG, Evered DE, Hall R, et al. The spectrum of thyroid disease in a community: the Wickham study. Clin Endocrinol 1977; 7: 481-493.
2. Volpé R. Graves’ disease. In: Baverman LE, Utiger RD, eds. The thyroid. 6th edn. Philadelphia: Lippincott Co, 1991: 648-657.
3. Fagel WJ, Vijver JCM van der. Oorzaken van thyreotoxicose bij 242 patienten. Ned tijdschr Geneeskd 1986; 130: 1406-1410.
4. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin recptor antibodies on long term remission after medical therapy of Graves’ disease. J Clin Endocrinol Metab 1994; 78: 98-102.
5. Foster Jr RS. Morbidity and mortality after thyroidectomy. Surg Gynecol Obstet 1978; 146: 423-429.
6. Hennemann G, Krenning EP, Sankaranarayanan K. Place of radioactive iodine in treatment of thyrotoxicosis. Lancet 1986; 1: 1369-1372.
7. Nordyke RA, Gilbert Jr FI. Optimal Iodine-131 dose for eliminating hyperthyroidism in Graves’ disease. J Nucl Med 1991; 32: 411-416.
8. Kendall-Taylor P, Keikr MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long-term follow-up study. Br Med J 1984; 289: 361-363.
9. Scott GR, Forfar JC, Toft AD. Graves’ disease and atrial fibrillation: the case for even higher doses of therapeutic iodine-131. Br Med J 1984; 289: 399-400.
10. 131I treatment of hyperthyroidism. Ann Intern Med 1972; 76: 721-723.
11. Becker DV, McConahey WM, Dobyns BM, et al. The results of radioiodine treatment of hyperthyreoidism. A preliminary report of the Thyrotoxicosis Therapy Follow-up Study. In: Fellinger K, Hofer R, eds. Further advances in thyroid research, vol 1. Vienna: Verlage der Wiener Medizinischen Akademie, 1971: 603-609.
12. Hardisty CA, Jones SJ, Hedley AJ, Munro DS, Bewsher PD, Weir RD. Clinical outcome and costs of care in radioiodine treatment of hyperthyreoidism. J R Coll Physicians Lond 1990; 24: 36-42.
13. Alevizaki CC, Alevizaki Harhalaki MC, Ikkos DG. Radioiodine-131 treatment of thyreotoxicosis: dose required for and some factors affecting the early induction of hypothyreoidism. Eur J Nucl Med 1985; 10: 450-454.
14. Glinoer D, Hesch D, Lagasse R, Laurberg P. The management of hyperthyroidism due to Graves’ disease in Europe in 1986. Results of an international survey. Acta Endocrinologica 1987; 115(Suppl. 285): 6-18.
15. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves’ disease. J Clin Endocrinol Metab 1990; 70: 1518-1524.
16. Goolden AWG, Russel Fraser T. Treatment of thyrotoxicosis with low doses of radioactive iodine. Br Med J 1969; 3: 442-443.
17. Freedberg AS, Kurland GS, Chamovitz DL, Ureles AL. A critical analysis of the quantitative 131-I therapy of thyrotoxicosis. J Clin Endocrinol Metab 1952; 12: 86-111.
18. Blahd WH, Hays MT. Graves’ disease in the male. A review of 241 cases treated with an individually calculated dose of sodium iodide 131-I. Arch Intern Med 1972; 129: 33-40.
19. Hagen GA, Ouelette RP, Chapman EM. Comparison of high and low dosage levels of 131-I in the treatment of thyrotoxicosis. N Engl J Med 1967; 277: 559-562.
20. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves’ hyperthyreoidism with radioiodine: results of a prospective randomized study. Thyroid 1997; 7: 247-251.
21. McDougall IR. The importance of obtaining thyroid uptake measurement in patients with hyperthyroidism. Nucl Med Commun 1990; 11: 73-76.
22. Bruin de TWA, Croon CWL, Klerk de JMH, Isselt van JW. Standardized radioiodine therapy in Graves’ disease: the persistent effect of thyroid weight and radioidine uptake on outcome. J Intern Med 1994; 236: 507-513.
23. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radiodine therapy of Graves’ hyprthyroidism: standard vs calculated 131-iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25: 186-193.
24. Jarløv AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy in hyper-thyroidism worthwhile? Clin Endocrinol 1995; 43: 325-329.
25. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. Br Med J 1996; 313: 36-39.
26. Ware JH, Antman EM. Equivalence trials. N Engl J Med 1997; 337: 1159-1161.
27. Altman DG, Bland JM. Absence of evidence is not evidence of absence. Br Med J 1995; 311: 485.
28. Greenspan FS, Rapoport MB. In: Greenspan FS, ed. Basic and clinical endocrinology. 3rd edn. East Norwalk: Appleton and Lange, 1991: 188-246.
29. Larsen PR, Ingbar SH. The thyroid gland. In: Wilson JP, Foster DW, eds. Williams’ textbook of endocrinology. Philadelphia: Saunders Co., 1992: 359.
30. Tamai H, Kasagi K, Takaichi Y, et al. Development of spontaneous hypothyroidism in patients with Graves’ disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab 1989; 69: 49.
31. Wood LC, Ingbar SH. Hypothyroidism as a late sequela in patients with Graves’ disease treated with antithyroid agents. J Clin Invest 1979; 64: 1429-1436.
32. Berg G, Michanek A, Holmberg E, Nystrom E. Clinical outcome of radiodine treatment of hyperthyroidism: a follow-up study. J Intern Med 1996; 239: 165-171.
33. Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med 1996; 37: 228-232.
34. Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131-I therapy for Graves’ disease. N Engl J Med 1984; 311: 426-432.
35. Bliddal H, Hansen JM, Rogowski P, Johansen K, Friis T, Siersbaek-Nielsen K. 131-I treatment of diffuse and nodular toxic goiter with or without antithyroid agents. Acta Endocrinologica 1982; 99: 517-521.
36. Velkeniers B, Vanhaelst L, Cytryn R, Jonckheer MH. Treatment of hyperthyroidism with radioiodine: adjuctive therapy with antithyroid drugs reconsidered. Lancet 1988; 1: 1127-1129.
37. Jarløv AE, Hegedus L, Gjorup T, Hansen JEM. Accuracy of the clinical assessment of thyroid size. Dan Med Bull 1991; 38: 87-89.
38. Nordmeyer JP, Simons M, Wenzel C, Scholten T. How accurate is the assessment of thyroid volume by palpation? A prospective study of 316 patients. Exp Clin Endocrinol Diab 1997; 105: 366-371.
39. Tannahill AJ, Hooper MJ, England M, Ferriss JB, Wilson GM. Measurement of thyroid size by ultrasound, palpation and scintiscan. Clin Endocrinol 1978; 8: 483-486.
40. Irvine WJ, Toft AD. The diagnosis and treatment of thyrotoxicosis. Clin Endocrinol 1976; 5: 687-707.
41. Solomon DH. Radioiodine. Iodine-131. In: Ingbar SH, Braverman LE, eds. The thyroid, 5th edn. Philadelphia: JB Lippincott Co., 1986: 1001-1003.
42. Tsuruta M, Nagayama Y, Yokoyama N, Izumi M, Nagataki S. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves’disease based on measurement of thyroid volume by ultrasonography. Ann Nucl Med 1993; 7: 193-197.